Capricor Therapeutics, Inc. (CAPR)

5,30 -0,12 (-2,21%) Alla chiusura: 04:00PM EDT

Capricor Therapeutics, Inc.

10865 Road to the Cure
Suite 150
San Diego, CA 92121
United States
858 727 1755
https://www.capricor.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 101

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Frank Isaac Litvack FACC, M.D.	Executive Chairman of the Board	120k	N/D	1956
Dr. Linda Marbán Ph.D.	Co-Founder, President, CEO & Director	280,62k	N/D	1963
Mr. Anthony J. Bergmann M.B.A.	CFO & Corporate Treasurer	437k	N/D	1986
Ms. Karen G. Krasney	Executive VP, General Counsel & Secretary	426,72k	N/D	1953
Dr. Kristi A. H. Elliott Ph.D.	Chief Science Officer	N/D	N/D	N/D
Catherine Lee Kelleher	Consultant	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Capricor Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.